Genitourinary Cancers Clinical Trials & Research at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
genitourinary cancers clinical trials:
NRG-GU010 Guidance Study Phase III Randomized Trial of Genomic-Risk Stratified
Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And
Intensification Clinical Trial Evaluation
Treatment agent: Radiotherapy +/- Androgen Deprivation Therapy (ADT)
Physician:
Michael N. Corradetti
Study Coordinator: Beatrice Becker //
beatrice.becker@providence.org // 707-932-5164
Study Resources:
https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / NRG Oncology Clinical Trials
Location: Providence Queen of the Valley Medical Center, Napa, CA
Study for participants with metastatic Stage IV castration- sensitive prostate
cancer (Evopar)
Treatment agent: AZD5305 in Combination with Physician’s Choice New
Hormonal Agents
Physician: Dr Wes Lee
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
Study Details | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive
Prostate Cancer Receiving Physician's Choice New Hormonal Agents |
ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA
Study for participants with locally advanced unresectable or metastatic
solid tumors (Gastroesophageal junction and pancreatic tumors) expressing
CLDN18.2 (Clarity- TP01)
Treatment agent: AZD0901 as monotherapy and in combination with anti-cancer agents
Physician: Dr Ian Anderson
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
Study Details | AZD0901 in Participants With Advanced Solid Tumours Expressing
Claudin18.2 | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA